Compare PRPO & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | RPID |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 34.7M |
| IPO Year | 2000 | 2021 |
| Metric | PRPO | RPID |
|---|---|---|
| Price | $19.02 | $0.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 34.2K | ★ 148.4K |
| Earning Date | 11-10-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.15 | 2.78 |
| EPS | N/A | ★ N/A |
| Revenue | $24,049,000.00 | ★ $33,587,000.00 |
| Revenue This Year | $233.72 | $16.95 |
| Revenue Next Year | $22.61 | $17.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 29.77 | 19.74 |
| 52 Week Low | $17.79 | $0.65 |
| 52 Week High | $33.63 | $4.94 |
| Indicator | PRPO | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 21.85 |
| Support Level | $19.37 | N/A |
| Resistance Level | $24.78 | $2.18 |
| Average True Range (ATR) | 1.01 | 0.06 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 37.67 | 13.72 |
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
Rapid Micro Biosystems Inc is a life sciences technology company. Its technology uses a sensitive camera and the natural autofluorescence of living cells to identify and quantify microbial growth faster and more accurately than the traditional method, which relies on the human eye. The company develops, manufactures, markets, and sells Growth Direct systems (Systems), proprietary consumables, laboratory information management system (LIMS) connection, and other software and services to address rapid microbial analysis used for quality control in the manufacture of pharmaceuticals, medical devices, and personal care products. Geographically, it generates maximum revenue from the United States, and the rest from Switzerland, Germany, Japan, and all other countries.